$BIIB (Biogen Inc.)

$BIIB {{ '2016-09-26T13:28:49+0000' | timeago}} • Announcement

$BIIB and $IONS said $BIIB closed rolling submission of a New Drug Application (NDA) to the FDA for approval of nusinersen, an investigational treatment for spinal muscular atrophy (SMA). $BIIB has also applied for Priority Review which, if granted, would shorten the review period of nusinersen after the Agency's acceptance of the NDA.

$BIIB {{ '2017-12-04T13:48:11+0000' | timeago}} • Announcement

$BIIB appointed Mark Hernon as SVP, Chief Information Officer, effective Dec. 4, 2017. In his new role, Hernon will lead the global IT organization and be responsible for accelerating and supporting the company's operations through delivery of innovative technology capabilities, systems, and tools.

$BIIB {{ '2017-11-21T13:53:38+0000' | timeago}} • Announcement

$BIIB appoints Jeffrey Capello as EVP and CFO effective as of Dec. 11, 2017. Capello will lead the company's Business Planning, Tax, Treasury, Internal Audit, Accounting, and IR functions and will report to Michel Vounatsos, CEO. He will be based in Cambridge, Mass. Most recently Capello was EVP and CFO of Beacon Health Options Inc.

$BIIB {{ '2017-10-30T14:48:41+0000' | timeago}} • Webcast

$BIIB said it is positive about the potential of its gene therapy program in Spinal Muscular Atrophy and expects to advance into the clinic in mid-2018. On SPINRAZA, $BIIB expects strong patient uptake for rest of 2017 globally. However, due to the dosing scheduling impact, expects SPINRAZA revenue growth to be mostly driven by ex-U.S. markets.

$BIIB {{ '2017-10-30T14:45:47+0000' | timeago}} • Webcast

On operating model restructuring, $BIIB commented that it expects to redirect up to $400MM by the end of 2020 to be reinvested in prioritized research and development and commercial value-creation opportunities. To achieve this goal, the company expects to make total expenditures of up to $170MM, primarily in 2018, through a restructuring program.

$BIIB {{ '2017-10-30T14:44:00+0000' | timeago}} • Webcast

$BIIB said that in 3Q17 its multiple sclerosis business delivered to its expectations. The company added that it expects its multiple sclerosis business to be the driver of near and midterm performance and a significant source of cash generation going forward.

$BIIB {{ '2017-10-24T14:01:43+0000' | timeago}} • Announcement

Biotech giant $BIIB reported a 18.7% jump in its 3Q17 earnings, driven by revenue growth and strong SPINRAZA sales. Profit jumped to $1.2Bil from $1Bil a year ago, while diluted EPS grew to $5.79 per share from $4.71. Revenue also grew YoY, driven by Multiple sclerosis and SPINRAZA growth. On a non-GAAP basis, $BIIB earned $6.31 per share.

$BIIB {{ '2017-10-24T12:56:50+0000' | timeago}} • Infographic

$BIIB Biogen Inc. Earnings AlphaGraphic: Q3 2017 Highlights

$BIIB {{ '2017-10-24T11:10:56+0000' | timeago}} • Announcement

$BIIB on its expanded agreement with Eisai Co., Ltd said it will continue to lead the ongoing Phase 3 development of aducanumab and will remain solely responsible for all development costs for aducanumab until April 2018. Eisai will then reimburse Biogen for 15% of expenses from April 2018 through Dec. 2018, and 45% from Jan. 2019 onwards.

$BIIB {{ '2017-10-24T11:00:55+0000' | timeago}} • Announcement

$BIIB and Eisai Co., Ltd. have expanded their existing agreement to jointly develop and commercialize investigational Alzheimer’s disease treatments. Under the terms of the agreement Eisai has exercised its option to co-develop and co-promote aducanumab, $BIIB's investigational anti-amyloid beta antibody for patients with Alzheimer's disease.

$BIIB {{ '2017-09-25T14:11:23+0000' | timeago}} • Announcement

$BIIB appointed Camille Lee as Senior Vice President, Alzheimer’s Therapeutic Area, effective immediately. In this new role, she will report directly to Chief Medical Officer Alfred Sandrock, Jr., M.D., Ph.D. and will be based in Cambridge.

$BIIB {{ '2017-09-12T12:31:48+0000' | timeago}} • Announcement

$BIIB named Sanjay Jariwala as SVP, Worldwide Medical. Jariwala will be responsible for leading and driving $BIIB's Worldwide Medical strategy working closely with the company’s global therapeutic operations and R&D leadership teams. He will be based in Cambridge, Massachusetts, and report directly to Chief Medical Officer Alfred Sandrock, Jr.

$BIIB {{ '2017-07-31T14:52:32+0000' | timeago}} • Announcement

$BIIB named Anabella Villalobos as SVP, Biotherapeutic & Medicinal Sciences. Villalobos will lead the company's Biotherapeutic & Medicinal Sciences organization in the delivery of high-quality, differentiated molecules to the clinic. She will report to Michael Ehlers, EVP, Head of Research and Development.

$BIIB {{ '2017-07-26T13:59:55+0000' | timeago}} • Webcast

In multiple sclerosis, $BIIB's 2Q17 global TECFIDERA revenue growth was driven by volume growth, while patient growth in TECFIDERA was driven by its newly launched markets such as Italy, Poland & Japan. For FY17 ex-US, $BIIB expects SPINRAZA revenues to be modest, mainly from Germany and Japan. However, patient intake in the US is expected to grow.

$BIIB {{ '2017-07-26T13:46:38+0000' | timeago}} • Webcast

$BIIB's priority for capital deployment going forward is to invest in building its pipeline across its core growth areas like Alzheimer's, Parkinson's and neuromuscular disease and emerging areas like pain, ophthalmology and neuropsychiatry. $BIIB expects to have about $400MM available by 2019 for R&D and commercial value creation opportunities.

$BIIB {{ '2017-07-25T15:15:33+0000' | timeago}} • Announcement

$BIIB named Alisha Alaimo as SVP of US Therapeutic Operations. In this position, Alaimo will lead $BIIB's sales and marketing, market access, patient services and commercial operations and strategy. Alaimo will join the company from $NVS, where she was VP and Head of its Cardiovascular Business Unit.

$BIIB {{ '2017-07-25T15:07:04+0000' | timeago}} • Announcement

On a segment basis, $BIIB's revenue for TECFIDERA, PLEGRIDY and FAMPYRA increased YoY in 2Q17, while total Total Interferon and AVONEX reported decline in revenues. In other products, Biosimilars revenue surged significantly to $91MM in the quarter from $15MM a year ago.

$BIIB {{ '2017-07-25T14:59:43+0000' | timeago}} • Announcement

Drugmaker $BIIB increased its revenue outlook for FY17 to $11.5-11.8Bil, due to faster than expected adoption of SPINRAZA in the US. GAAP diluted EPS guidance was narrowed to $17.05-17.65 from the earlier guidance of $18-18.80. Adjusted EPS guidance, however, was raised to $20.80-21.40 from the prior guidance of $20.45-21.25.

$BIIB {{ '2017-07-25T14:47:25+0000' | timeago}} • Announcement

$BIIB, which competes with $ABT and $PFE, posted record 2Q17 revenue, on strong Spinraza demand in the US, though YoY profit fell 18% on higher expenses. Net earnings attributable to Biogen plunged to $862.8MM, while diluted EPS fell 15.03% to $4.07. Revenue, however, jumped 6% to $3.1Bil. $BIIB lifted its outlook due to strong Spinraza sales.

$BIIB {{ '2017-07-25T12:18:23+0000' | timeago}} • Announcement

$BIIB Biogen Inc. Earnings AlphaGraphic: Q2 2017 Highlights

$BIIB {{ '2017-07-10T12:58:24+0000' | timeago}} • Announcement

$BIIB appointed Amy Chevalier Efantis as VP of Government Affairs, effective July 17. Efantis brings more than two decades of legislative, public policy, and advocacy experience in the biopharma industry and the public sector. She will lead the company's federal and state government affairs activities from $BIIB's Washington, D.C., office.

Recent Transcripts

MDT (Medtronic plc)
Tuesday, November 21 2017 - 1:00pm
SGMO (Sangamo Biosciences Inc.)
Thursday, November 9 2017 - 10:00pm
ONVO (Organovo Holdings, Inc.)
Thursday, November 9 2017 - 10:00pm
BTX (BioTime, Inc.)
Thursday, November 9 2017 - 9:30pm
ENDP (Endo International plc)
Thursday, November 9 2017 - 9:30pm
CNCE (Concert Pharmaceuticals, Inc.)
Thursday, November 9 2017 - 1:30pm
RGEN (Repligen Corporation)
Thursday, November 9 2017 - 1:30pm
VRML (Vermillion, Inc.)
Wednesday, November 8 2017 - 9:30pm
REGN (Regeneron Pharmaceuticals, Inc.)
Wednesday, November 8 2017 - 1:30pm
CCXI (ChemoCentryx, Inc.)
Tuesday, November 7 2017 - 10:00pm
QGEN (Qiagen NV)
Tuesday, November 7 2017 - 2:00pm
ATRS (Antares Pharma Inc.)
Tuesday, November 7 2017 - 1:30pm
PTLA (Portola Pharmaceuticals, Inc.)
Monday, November 6 2017 - 9:30pm
AGN (Allergan plc)
Wednesday, November 1 2017 - 12:30pm
AMRN (Amarin Corporation plc)
Wednesday, November 1 2017 - 12:00pm
TECH (Bio-Techne Corp.)
Tuesday, October 31 2017 - 1:00pm
ACOR (Acorda Therapeutics, Inc.)
Tuesday, October 31 2017 - 12:30pm
SGEN (Seattle Genetics, Inc.)
Thursday, October 26 2017 - 8:30pm
GILD (Gilead Sciences Inc.)
Thursday, October 26 2017 - 8:30pm
BMY (Bristol-Myers Squibb Company)
Thursday, October 26 2017 - 2:30pm

AlphaGraphics you may like